Patient and Caregiver Stories

Share
NEWS ABOUT DARZALEX®

PATIENT SITE

Discover

More Possibilities

A new option for patients with multiple myeloma: DARZALEX® can now be used in combination with Revlimid® (lenalidomide) and dexamethasone or Velcade® (bortezomib) and dexamethasone in patients who have received at least one prior medicine.

How does DARZALEX® work?
  • DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
  • DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
RESULTS SEEN IN CLINICAL TRIALS
  • The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
    • Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
  • The majority of patients responded to the following DARZALEX® combination treatments:
    • ​DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
      • 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
    • DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
      • Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
  • DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%

Sign up to receive updates and more information.

Click here if you are a healthcare professional.

Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Read stories from patients on DARZALEX® and their caregivers about their experiences

Debby | Patient

Living with multiple myeloma since 2009

Patient Debby Living with Multiple Myeloma Story

For Debby, it has been a long journey living with multiple myeloma, and one that involved numerous treatments, several setbacks, and the eventual reality that she was a patient who was resistant to many types of treatment. After several lines of therapy, she has navigated the course of her multiple myeloma with the help of her “cancer caddie” husband, for whose support she will always be greatful. 

Read Debby’s Story

Read Her Caregiver’s Story

Harry | Caregiver

Caregiver since 2009

Caregiver Harry Caring for Someone with Multiple Myeloma Story

For Harry, being a caregiver is a lot like being a well-educated caddie who needs to know as much about the course of Debby’s multiple myeloma as possible. He’s been with Debby every step of the way, staying informed, so when she started on DARZALEX®, he was able to better understand how it could impact her. He hopes caregivers are able to relate to his story so they can assist their loved ones in navigating their multiple myeloma course.

Read Harry’s Story

Read Debby’s Story

E.C. | Patient

Living with multiple myeloma since 2010

Patient E.C Living With Multiple Myeloma Story

For E.C., retirement was not going to slow him down. He was living with his wife, Lynn, in their “dream home” in North Carolina and was active in sports and his community. After a doctor’s appointment for an unrelated injury, further tests were conducted, leading to a multiple myeloma diagnosis. He then began his roller-coaster journey of treatment and relapse. E.C. encourages those living with multiple myeloma to keep open lines of communication with caregivers, loved ones, and healthcare professionals.

Read E.C.’s Story